Largest-Ever Analysis Reveals Which Lymphoma Drug Combination Works Best
A systematic review and meta-analysis of 70 clinical studies finds that newer BTK inhibitors acalabrutinib and zanubrutinib outperform ibrutinib as ...
A systematic review and meta-analysis of 70 clinical studies finds that newer BTK inhibitors acalabrutinib and zanubrutinib outperform ibrutinib as ...
A systematic review of 542 patients finds ruxolitinib-based regimens achieve an 87.2 percent overall response rate in hemophagocytic lymphohistiocytosis, with ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine